Evidence map›Paper›PMID 27070314›Full record

ArticlePloS one2016

Cycloart-24-ene-26-ol-3-one, a New Cycloartane Isolated from Leaves of Aglaia exima Triggers Tumour Necrosis Factor-Receptor 1-Mediated Caspase-Dependent Apoptosis in Colon Cancer Cell Line.

Kok Hoong Leong, Chung Yeng Looi, Xe-Min Loong, Foo Kit Cheah, Unang Supratman, Marc Litaudon, Mohd Rais Mustafa, Khalijah Awang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Cytotoxic Effects of Chlorophyllides in Ethanol Crude Extracts from Plant Leaves.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  7. Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  8. Article
  9. Article
  10. BioMed research international · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Kok Hoong LeongDepartment of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID http://orcid.org/0000-0002-7317-6117
Chung Yeng LooiDepartment of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Xe-Min LoongDepartment of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
Foo Kit CheahDepartment of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Unang SupratmanDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Padjadjaran University, Jatinangor, Indonesia.
Marc LitaudonCentre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS 1, Avenue de la Terrasse, Gif-sur-Yvette Cedex, France.
Mohd Rais MustafaCenter for Natural Product and Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
Khalijah AwangCenter for Natural Product and Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
University of Malaya · MYCentre National de la Recherche Scientifique · FRPadjadjaran University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plants in the Meliaceae family are known to possess interesting biological activities, such as antimalaral, antihypertensive and antitumour activities. Previously, our group reported the plant-derived compound cycloart-24-ene-26-ol-3-one isolated from the hexane extracts of Aglaia exima leaves, which shows cytotoxicity towards various cancer cell lines, in particular, colon cancer cell lines. In this report, we further demonstrate that cycloart-24-ene-26-ol-3-one, from here forth known as cycloartane, reduces the viability of the colon cancer cell lines HT-29 and CaCO-2 in a dose- and time-dependent manner. Further elucidation of the compound's mechanism showed that it binds to tumour necrosis factor-receptor 1 (TNF-R1) leading to the initiation of caspase-8 and, through the activation of Bid, in the activation of caspase-9. This activity causes a reduction in mitochondrial membrane potential (MMP) and the release of cytochrome-C. The activation of caspase-8 and -9 both act to commit the cancer cells to apoptosis through downstream caspase-3/7 activation, PARP cleavage and the lack of NFkB translocation into the nucleus. A molecular docking study showed that the cycloartane binds to the receptor through a hydrophobic interaction with cysteine-96 and hydrogen bonds with lysine-75 and -132. The results show that further development of the cycloartane as an anti-cancer drug is worthwhile.

Indexed as

AglaiaAntineoplastic AgentsApoptosisCaco-2 CellsCaspasesCell Line, TumorCell SurvivalColonic NeoplasmsCytochromes cHT29 CellsHumansMembrane Potential, MitochondrialMitochondriaPlant LeavesReceptors, Tumor Necrosis Factor, Type ITriterpenesAntineoplastic AgentsCaspasescycloartaneCytochromes cReceptors, Tumor Necrosis Factor, Type ITriterpenes

Identifiers

PMID27070314
PMCPMC4829234
OpenAlexW2338099077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.